Larvol Cliniclarvol.hashnode.dev·Aug 16, 2024Phase I Study of ARX788 in HER2-Positive Metastatic Breast Cancer: Safety and EfficacyAbstract Purpose: ARX788 is a novel antibody-drug conjugate (ADC) comprised of an anti-HER2 mAb and a potent tubulin inhibitor payload AS269 that is site-specifically conjugated to the antibody via a nonnatural amino acid incorporated into the antibo...Cancer
Larvol Cliniclarvol.hashnode.dev·Aug 8, 2024Phase I Study of ARX788 in HER2-Positive Metastatic Breast Cancer: Safety and EfficacyPurpose: ARX788 is a novel antibody-drug conjugate (ADC) comprised of an anti-HER2 mAb and a potent tubulin inhibitor payload AS269 that is site-specifically conjugated to the antibody via a nonnatural amino acid incorporated into the antibody. Herei...Cancer
Larvol Cliniclarvol.hashnode.dev·Aug 8, 2024Trial: Ponatinib vs Imatinib in Ph+ ALLImportance: In newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), disease progression due to acquired resistance to first- or second-generation BCR::ABL1 tyrosine kinase inhibitors is common. Ponatinib inhibits...Cancer
